The global Artificial Intelligence (AI) in Drug Discovery market is rapidly expanding, driven by breakthroughs in data science, increased prevalence of chronic diseases, and a growing need to expedite the drug development process. According to Fortune Business Insights, the market was valued at USD 3.00 billion in 2022 and is projected to reach USD 7.94 billion by 2030, growing at a CAGR of 12.2% during the forecast period (2023–2030).

Request a Free Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/artificial-intelligence-in-drug-discovery-market-105354 

Top Companies in the Market

• Microsoft (U.S.)
• Schrödinger, Inc. (U.S.)
• Cresset (U.K.)
• IBM (U.S.)
• Atomwise Inc. (U.S.)
• Insilico Medicine (U.S.)
• Exscientia (U.K.)
• BenevolentAI (U.K.)
• Aria Pharmaceuticals, Inc. (U.S.)
• Integral BioSciences (U.S.)
• Alphabet Inc. (U.S.)

Key Industry Development

November 2022: Cyclica received a USD 1.8 million grant from the Bill & Melinda Gates Foundation to enhance its AI-enabled drug discovery platform for developing new non-hormonal contraceptives. The project focuses on targeting multiple low-data biological pathways and underlines the importance of AI in solving complex drug discovery challenges.

Market Drivers

• Rising Chronic Disease Burden: Increasing global incidences of cancer, cardiovascular diseases, and metabolic disorders are driving the need for faster, more cost-effective therapeutic solutions.
• AI's Predictive Capabilities: AI enhances the ability to model biological processes, identify druggable targets, and validate potential therapies with high accuracy.
• Collaborations and Partnerships: Leading pharmaceutical companies are partnering with AI startups to reduce R&D costs and time-to-market.
• COVID-19 Acceleration: The pandemic showcased AI’s potential in accelerating vaccine trials and identifying treatment compounds.

Market Restraints

• High Implementation Costs: Integrating AI into existing R&D frameworks requires significant capital investment.
• Data Quality and Integration: Fragmented and inconsistent datasets can affect model accuracy and delay discovery timelines.
• Regulatory Uncertainty: The evolving nature of AI in healthcare poses challenges in regulatory approvals and compliance.

Market Coverage

The market is extensively segmented based on drug type, offering, technology, application, end-user, and region. The report offers a granular view of industry dynamics and provides actionable insights for stakeholders across the value chain.

Ask For Customization: https://www.fortunebusinessinsights.com/enquiry/ask-for-customization/artificial-intelligence-in-drug-discovery-market-105354 

Market Competitive Landscape

Industry competition is intensifying as established tech giants and pharmaceutical companies invest in AI R&D. Strategic alliances and licensing deals are on the rise:

• In January 2022, Sanofi collaborated with Exscientia to leverage AI for metabolic disease research.
• In November 2022, Insilico Medicine announced a USD 1.2 billion deal with Sanofi to discover up to six new therapeutic targets using its AI platform Pharma.AI.

These developments underscore the trust placed in AI platforms to transform the future of drug discovery.

Market Segments

By Drug Type

• Small Molecule: Dominates the market due to ease of synthesis and AI’s capability in modeling small compounds efficiently.
• Large Molecule: Growing adoption in biologics and complex therapeutic areas such as oncology and autoimmune disorders.

By Offering

• Software: Includes AI-based platforms and tools for molecular modeling, target identification, and screening.
• Services: Comprises consultancy, integration, and research support for pharma clients adopting AI.

By Technology

• Machine Learning
• Natural Language Processing
• Others (e.g., neural networks, deep learning)

Regional Insights

North America held the dominant market share of 69.33% in 2022, owing to advanced healthcare infrastructure, strong presence of AI companies, and active R&D investment. Europe and Asia Pacific are also expected to witness robust growth due to rising healthcare awareness and government support for AI initiatives.

Get A Quote: https://www.fortunebusinessinsights.com/enquiry/get-a-quote/artificial-intelligence-in-drug-discovery-market-105354

Future Market Scope

The future of AI in drug discovery looks promising as technological advancements continue to redefine the research landscape. Key trends shaping the future include:

• AI-powered Target Discovery: Tools capable of proteome-wide virtual screening are transforming early-stage R&D.
• Cloud Integration: Cloud computing is enabling large-scale simulation and collaborative research across borders.
• Personalized Medicine: AI is enabling more precise, individualized drug discovery by analyzing genetic, epigenetic, and phenotypic data.

As AI continues to evolve, its integration with drug discovery will lead to faster innovation, lower development costs, and better patient outcomes. Stakeholders must embrace this technological revolution to remain competitive and meet future healthcare demands.

Contact us:

Fortune Business Insights™ Pvt.

Phone: USA: +1 833 909 2966 (Toll-Free),

United Kingdom: +44 808 502 0280 (Toll-Free),

APAC: +91 744 740 1245

Email: [email protected]